Online inquiry

IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12746MR)

This product GTTS-WQ12746MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TIGIT gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_173799.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 201633
UniProt ID Q495A1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12746MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15740MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ1882MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGEN1884
GTTS-WQ7209MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ7220MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ13962MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ13497MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ9243MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ15123MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SYD985
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW